These results suggested that ATM-mediated signaling is operational and activated in CP-CML [20], implying that the ATM/Chk2/p53 checkpoint signaling induced by the BCR-ABL oncogene may protect CP-CML cells against the blast crisis. The gene discussed is CHEK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.